Breast Cancer
Clinical research in breast cancer focuses on hormone receptor-positive, HER2-negative disease in older patients, with interest in combining endocrine treatment, CDK4/6 inhibition, and hypofractionated radiotherapy for newly diagnosed cases that are not immediately operable.
- Hormone therapy
- Radiotherapy
- CDK4/6-targeted treatment
The sponsor’s work in this area reflects a therapeutic focus on locally advanced and elderly-patient management within oncology.
Acute Myeloid Leukemia
Research in acute myeloid leukemia centers on relapsed or refractory AML with FLT3 mutations, including interest in integrating gilteritinib with established gemtuzumab ozogamicin-based treatment platforms.
- FLT3-mutated AML
- Relapsed/refractory disease
- Targeted leukemia therapy
This area highlights involvement in molecularly defined hematologic malignancies and treatment combinations for resistant disease.
Soft Tissue Sarcoma
In soft tissue sarcoma, the clinical focus is on oligometastatic disease and the use of stereotactic body radiotherapy with immunomodulation, particularly involving atezolizumab alongside high-dose radiation.
- Oligometastatic sarcoma
- Immunotherapy
- Stereotactic irradiation
The sponsor’s sarcoma portfolio is centered on advanced radiation-based strategies in combination with immune checkpoint inhibition.
Glioblastoma and Lung Carcinoma
Research activity also extends to glioblastoma and small cell lung carcinoma, with interest in maintenance approaches using pazopanib and temozolomide in brain tumors, and carbonic anhydrase inhibition combined with radiochemotherapy or radioimmunotherapy in lung cancer.
- Glioblastoma maintenance therapy
- Small cell lung carcinoma
- Combined modality treatment
These studies show interest in difficult-to-treat solid tumors where radiation, chemotherapy, and targeted therapy are explored together.
Precision Oncology Supportive Research
Additional clinical interest is seen in the use of capecitabine and the evaluation of DPD activity, indicating attention to treatment-related variability and individualized cancer therapy.
- Fluoropyrimidine metabolism
- Treatment response variability
- Individualized oncology care
This complements the sponsor’s broader involvement in solid tumors and hematologic cancer research.
